Clinical–alimentary tractCost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation
Section snippets
Patients
The EC-IBD created a prospective, uniformly diagnosed, population-based inception cohort of 2201 patients with inflammatory bowel disease within 20 well-described geographic areas in 11 European countries and Israel during the inception period from October 1, 1991 to September 30, 1993.10 The geographic regions and study area populations were described in detail previously. The population was required to be stable, with little immigration or emigration, and to number not less than 250,000
Cohort Characteristics
Fifteen patients with indeterminate colitis were excluded because their small number precluded analysis. The remaining 1324 inflammatory bowel disease patients included those with full data (1273 patients), demographics only (3 patients), diagnostics only (8 patients), and medications only (40 patients). The cost analysis was performed on 1321 patients with economic data, omitting the 3 patients who had only demographic records. Pertinent demographic and clinical features of these 1321 patients
Discussion
The present cost-analysis of health care in inflammatory bowel disease has several advantages over previous studies. The cohort considered of population-based, uniformly diagnosed, incident patients derived from 9 countries. The long study period captured 10 years of downstream costs related to the natural progression of the illness as modified by therapy. Information about resource use was as comprehensive as possible, incorporating data from the level of the general practitioner to the
References (29)
- et al.
Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital
Am J Gastroenterol
(2000) - et al.
Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort
Gastroenterology
(1999) - et al.
Fine particles and meteorological conditions are associated with lung function in children with asthma living near two power plants
Public Health
(2005) - et al.
The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal
Gastroenterology
(2004) - et al.
Best practice of health care in inflammatory bowel disease: a European survey
Eur J Intern Med
(2004) - et al.
The cost diary: a method to measure direct and indirect costs in cost-effectiveness research
J Clin Epidemiol
(2000) - et al.
Estimating medical care costs under conditions of censoring
J Health Economics
(2004) - et al.
Epidemiology of inflammatory bowel disease: an update
Scand J Gastroenterol
(1996) - et al.
Theoretical foundations of cost-effectiveness analysis
- et al.
Inflammatory bowel disease: costs-of-illness
J Clin Gastroenterol
(1992)
Inflammatory bowel disease: medical cost algorithms
J Clin Gastroenterol
Inflammatory bowel diseases: health care and costs in Sweden in 1994
Scand J Gastroenterol
Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital
J Gastroenterol Hepatol
Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study
Gut
Cited by (203)
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
2023, The Lancet Gastroenterology and HepatologyTreat to target in Crohn’s disease: A practical guide for clinicians
2024, World Journal of GastroenterologyIncidence and adverse clinical events of primary sclerosing cholangitis with ulcerative colitis
2023, International Journal of Colorectal DiseaseCrossing barriers: the burden of inflammatory bowel disease across Western Europe
2023, Therapeutic Advances in GastroenterologyIBD barriers across the continents: a continent-specific analysis: Latin America
2023, Therapeutic Advances in GastroenterologyLongitudinal trends in direct costs and healthcare utilization ascribable to inflammatory bowel disease in the biologic era: a nationwide, population-based study
2023, Journal of Gastroenterology and Hepatology (Australia)
Published in part as an abstract of similar title in Gastroenterology 2005;128(Suppl):A324.
Supported by the European Commission as a fifth framework shared cost action (QLG4-CT-2000-01414).